ClinicalTrials.Veeva

Find clinical trials for Leukemia in Nashville, TN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Myeloid Leukemia
Acute Myeloid Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Myelodysplastic Syndromes

Leukemia trials near Nashville, TN, USA:

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) as part of Phase 1. In Phase 2, assessment of ziftomenib wil...

Enrolling
Acute Leukemia of Ambiguous Lineage
Mixed Phenotype Acute Leukemia
Drug: Ziftomenib

Phase 1, Phase 2

Kura Oncology

Nashville, Tennessee, United States and 51 other locations

in treating pediatric and young adult patients with acute myeloid leukemia (AML) or acute leukemia of ambiguous lineage (ALAL) that...

Enrolling
Refractory Acute Leukemia of Ambiguous Lineage
Acute Myeloid Leukemia, in Relapse
Drug: Methotrexate
Drug: Venetoclax

Phase 1

St. Jude Children's Research Hospital
St. Jude Children's Research Hospital

Nashville, Tennessee, United States and 9 other locations

(bid) in approximately 540 participants with chronic lymphocytic leukemia (CLL). Participants will be enrolled into 3 following cohorts: tre...

Active, not recruiting
Chronic Lymphocytic Leukemia
Drug: Acalabrutinib

Phase 3

AstraZeneca
AstraZeneca

Nashville, Tennessee, United States and 105 other locations

GDX012 is a novel cell therapy developed for the treatment of certain types of cancer, including Acute Myeloid Leukemia (AML). The main aims...

Enrolling
Leukemia
Drug: Chemotherapy Agents
Drug: GDX012

Phase 1, Phase 2

Takeda
Takeda

Nashville, Tennessee, United States and 13 other locations

Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 70 will be randomized to receive gilteritinib ...

Active, not recruiting
Acute Myeloid Leukemia
Drug: Gilteritinib
Drug: Daunorubicin

Phase 2

PrECOG

Nashville, Tennessee, United States and 43 other locations

This study will evaluate the efficacy of uproleselan (GMI-1271), a specific E-selectin antagonist, in combination with chemotherapy to treat relapsed...

Active, not recruiting
Acute Myeloid Leukemia
Drug: Uproleselan
Drug: Placebo

Phase 3

GlycoMimetics

Nashville, Tennessee, United States and 69 other locations

chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (rux...

Active, not recruiting
Leukemia
Drug: Cytarabine
Drug: Leucovorin Calcium

Phase 2

Incyte
Incyte

Nashville, Tennessee, United States and 110 other locations

This first-in-human study will evaluate RVU120 (SEL120), a novel small molecule CDK8/19 inhibitor, in patients with Acute Myeloid Leukemia (...

Active, not recruiting
Acute Myeloid Leukemia
High-risk Myelodysplastic Syndrome
Drug: RVU120(SEL120)

Phase 1

Ryvu Therapeutics

Nashville, Tennessee, United States and 9 other locations

This study enrolled 472 participants, aged 55 or older, with a diagnosis of de novo acute myeloid leukemia (AML) or AML secondary to prior m...

Active, not recruiting
Leukemia, Myeloid, Acute
Drug: Placebo
Drug: Oral Azacitidine

Phase 3

Celgene
Celgene

Nashville, Tennessee, United States and 222 other locations

This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with relapsed/refractory T-ALL or T-LL...

Enrolling
T-Cell Lymphoblastic Leukemia/Lymphoma
Lymphoblastic Leukemia
Biological: BEAM-201

Phase 1, Phase 2

Beam Therapeutics

Nashville, Tennessee, United States and 6 other locations

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems